videoSlug

VideoSlug_VideoQuery

slug

VideoPageContentQuery

content

videos

query VideoSlug_VideoQuery(
  $videoSlug: String!
) {
  ...VideoPageContentQuery_1X4EH4
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment LatestVideos_Videos on Query {
  videos(first: 5, upcoming: false, order: {field: liveTime, direction: DESC}) {
    edges {
      node {
        id
        title
        lang
        pageUrl
        liveTime
        isLive
        companies {
          name
          squareLogoUrl
          id
        }
      }
    }
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment VideoPageContentQuery_1X4EH4 on Query {
  content(slug: $videoSlug, type: [VIDEO, WEBCAST]) {
    __typename
    id
    title
    slug
    lang
    htmlBody
    isPremium
    companies {
      viewerIsFollowing
      id
      name
      pageUrl
      defaultInstrument {
        id
        isin
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    createdAt
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    ... on Video {
      imgUrl
      videoEmbedUrl(location: "inderes")
      audioEmbedUrl
      registrationInfoHtml
      registrationUrl
      liveTime
    }
    ... on Webcast {
      imgUrl
      videoEmbedUrl(location: "inderes")
      registrationInfoHtml
      registrationUrl
      liveTime
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
  }
  ...LatestVideos_Videos
}


type

__typename

title

lang

htmlBody

isPremium

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

first

order

upcoming

edges

Equity Research Analyst

Philip Coombes

CEO, Sweden

Claus Thestrup

Gubra

The company combines the best of both worlds – a fast-growing, cash-generating CRO business serving top pharma companies and a high-risk, high-reward drug discovery pipeline. A landmark partnership with AbbVie, which includes upfront payments of USD 350m for its obesity drug, GUBamy, highlights its innovation potential.

With advanced AI platforms and new candidates like UCN2 in the pipeline, Gubra is positioned at the frontier of biotech. Watch the video to understand what the market is pricing in – and what could unlock further development? 


The company combines the best of both worlds &#x2013; a fast-growing, cash-generating CRO business serving top pharma companies and a high-risk, high-reward drug discovery pipeline. A landmark partnership with AbbVie, which includes upfront payments of USD 350m for its obesity drug, GUBamy, highlights its innovation potential.
With advanced AI platforms and new candidates like UCN2 in the pipeline, Gubra is positioned at the frontier of biotech. Watch the video to understand what the market is pricing in &#x2013; and what could unlock further development?&#xa0;
Disclaimer: HC Andersen Capital receives payment from Gubra for a DigitalIR/Corporate Visibility subscription agreement. The commentary is for informational purposes only and does not contain recommendations to buy, not to buy, sell or not to sell shares. / Philip Coombes 08:55 26/03/2025

HC Andersen Capital

Gubra: Understanding valuation (PoS) post Abbvie deal

AKTIER MED FRIIS - UGE 50 2025

Novo Nordisk

Bavarian Nordic

A.P. Møller - Mærsk

Pandora

FLSmidth & Co.

Nilfisk Holding

GN Store Nord

Flügger Group

HCA Morgenbørs 12/12 - Positive futures og fokus på FLSmidth og fedme aktier

Verve Group

A sit-down with CEO Remco Westermann

Aiforia Technologies

Aiforia as an Investment | Life Science Night Dec  9, 2025

GreenMobility

Zealand Pharma

HCA Morgenbørs 11/12 - Flade europæiske futures, Oracle skaber usikkerhed om AI

Recent videos